Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

• Главные авторы: Juanjuan Feng (Автор), Zhengke Lian (Автор), Xinting Xia (Автор), Yue Lu (Автор), Kewen Hu (Автор), Yunpeng Zhang (Автор), Yanan Liu (Автор), Longmiao Hu (Автор), Kun Yuan (Автор), Zhenliang Sun (Автор), Xiufeng Pang (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2023-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer...